Leo Pharma inks $300 million psoriasis deal with Virobay - Pharma Times

Leo Pharma inks $300 million psoriasis deal with Virobay Pharma present time Denmark's Leo Pharma has signed a deal with the US biotech Virobay to develop an investigational oral treatment for disease of the skin which "has the possible to be the archetypal on the market with its specific mode of action". The agreement faculty see Leo make AN ... and more » Link To Article